<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01451515</url>
  </required_header>
  <id_info>
    <org_study_id>NHL16</org_study_id>
    <secondary_id>NCI-2012-00496</secondary_id>
    <nct_id>NCT01451515</nct_id>
  </id_info>
  <brief_title>NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma</brief_title>
  <official_title>NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National University, Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Jude Children's Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II clinical trial using risk-adapted therapy. The treatment is acute&#xD;
      lymphoblastic leukemia (ALL)-based therapy, using multi-agent regimens comprising of&#xD;
      induction, consolidation, and continuation (maintenance) phases delivered over 24-30 months.&#xD;
      Participants will be classified into 3 treatment stratums, based on bone marrow/peripheral&#xD;
      blood lymphoma cells involvement at diagnosis and day 8 for T-lymphoblastic lymphoma and bone&#xD;
      marrow/peripheral blood lymphoma cells involvement at diagnosis for B-lymphoblastic lymphoma.&#xD;
&#xD;
      The Primary Objective of this study is:&#xD;
&#xD;
      To improve the outcome of children with lymphoblastic lymphoma (LL) who have minimal&#xD;
      disseminated disease (MDD) equal to or more than 1% at diagnosis by using MDD- and minimal&#xD;
      residual disease (MRD)- based risk-adapted therapy.&#xD;
&#xD;
      The Secondary Objectives of this study are:&#xD;
&#xD;
        -  To estimate the event-free survival and overall survival of children with lymphoblastic&#xD;
           lymphoma who are treated with MDD- or MRD-based risk- directed therapy.&#xD;
&#xD;
        -  To evaluate the prognostic value of levels of MDD at diagnosis and MRD on day 8 of&#xD;
           remission induction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TREATMENT PLAN&#xD;
&#xD;
      Treatment will consist of 3 main phases: remission induction, consolidation [only for&#xD;
      patients with any central nervous system (CNS) disease and/or testicular involvement], and&#xD;
      continuation.&#xD;
&#xD;
        -  Induction (6-7 weeks).&#xD;
&#xD;
        -  Consolidation for participants with CNS involvement or those with testicular disease&#xD;
           only (10 weeks).&#xD;
&#xD;
        -  Reintensification - Participants with residual disease any time after induction therapy&#xD;
           may receive 1-2 cycles of re-intensification therapy and may proceed to allogeneic stem&#xD;
           cell transplant if suitable donor is available.&#xD;
&#xD;
        -  Continuation Therapy (98-120 weeks).&#xD;
&#xD;
        -  Intrathecal Chemotherapy (days 1 and 15; if needed also on days 8 and 22)&#xD;
&#xD;
      TREATMENT SCHEME&#xD;
&#xD;
      T lymphoblastic lymphoma: bone marrow/peripheral blood (BM/PB) involvement (MDD/MRD):&#xD;
      Diagnosis: less than 1%; Day 8: +/- (Stratum 1)&#xD;
&#xD;
        -  Induction&#xD;
&#xD;
             -  Single dose of Cyclophosphamide&#xD;
&#xD;
             -  Steroid: prednisone&#xD;
&#xD;
        -  Continuation: 98 weeks&#xD;
&#xD;
      T lymphoblastic lymphoma: BM/PB involvement (MDD/MRD): Diagnosis: equal to or greater than&#xD;
      1%; Day 8: - (Stratum 2)&#xD;
&#xD;
        -  Induction&#xD;
&#xD;
             -  Fractionated Cyclophosphamide&#xD;
&#xD;
             -  Steroid: prednisone&#xD;
&#xD;
        -  Continuation : 98 weeks&#xD;
&#xD;
      T lymphoblastic lymphoma: BM/PB involvement (MDD/MRD): Diagnosis: equal to or greater than&#xD;
      1%; Day 8: + (Stratum 3)&#xD;
&#xD;
        -  Induction&#xD;
&#xD;
             -  Fractionated Cyclophosphamide&#xD;
&#xD;
             -  Steroid: prednisone and dexamethasone&#xD;
&#xD;
        -  Continuation: 120 weeks&#xD;
&#xD;
      B lymphoblastic lymphoma: Stage I-III (Stratum 1)&#xD;
&#xD;
        -  Induction&#xD;
&#xD;
             -  Single dose of Cyclophosphamide&#xD;
&#xD;
             -  Steroid: prednisone&#xD;
&#xD;
        -  Continuation: 98 weeks&#xD;
&#xD;
      B lymphoblastic lymphoma: Stage IV or testicular (Stratum 2)&#xD;
&#xD;
        -  Induction&#xD;
&#xD;
             -  Fractionated Cyclophosphamide&#xD;
&#xD;
             -  Steroid: prednisone&#xD;
&#xD;
        -  Continuation: 98 weeks&#xD;
&#xD;
      Patients with CNS or testicular involvement will receive Consolidation therapy prior to&#xD;
      continuation therapy and receive extended maintenance therapy (120 weeks).&#xD;
&#xD;
      Any patient with detectable disease (MRD, bone marrow or biopsy of residual mass) at the end&#xD;
      of induction may be considered for reintensification and/or hematopoietic stem cell&#xD;
      transplantation (HSCT).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 25, 2012</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Actual">May 8, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival (EFS).</measure>
    <time_frame>Two years post therapy.</time_frame>
    <description>Kaplan-Meier survival curve estimate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS).</measure>
    <time_frame>Two years post therapy.</time_frame>
    <description>Kaplan-Meier survival curve estimate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of lymphoblastic cells in bone marrow at diagnosis (MDD) and at day 8 of therapy (MRD).</measure>
    <time_frame>Two years post day 8.</time_frame>
    <description>Cox regression modeling of EFS with MRD and MDD as explanatory variables.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Lymphoblastic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will undergo treatment as described in the intervention section. Interventions include:&#xD;
Remission induction: prednisone, vincristine, daunorubicin, PEG-asparaginase (or Erwinia asparaginase), IT-MHA (Methotrexate, hydrocortisone, and cytarabine), cyclophosphamide, cytarabine, thioguanine&#xD;
Consolidation: PEG-asparaginase, High-dose methotrexate (HD-MTX), mercaptopurine&#xD;
Postremission continuation: Dexamethasone, doxorubicin, vincristine, mercaptopurine, PEG-asparaginase, cyclophosphamide, cytarabine, methotrexate&#xD;
Reintensification: dexamethasone, cytarabine, etoposide, PEG-asparaginase, clofarabine, cyclophosphamide&#xD;
All patients receive IT-MHA on days 1 and 15. Some patients also receive additional IT-MHA on days 8 and 22.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Given orally (PO).</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Prednisolone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Given intravenously (IV).</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Oncovin®</other_name>
    <other_name>Vincristine sulfate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin</intervention_name>
    <description>Given IV.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Daunomycin</other_name>
    <other_name>Cerubidine®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-asparaginase</intervention_name>
    <description>Given intramuscularly (IM) or IV.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Pegaspargase</other_name>
    <other_name>Oncaspar®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erwinia asparaginase</intervention_name>
    <description>Given IM or IV if allergy occurs with the first or second PEG-asparaginase dose.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Erwinase®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Given IV.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Adriamycin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Cytoxan®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IV or IT.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Ara-C</other_name>
    <other_name>Cytosar-U®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thioguanine</intervention_name>
    <description>Given PO.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Purine antimetabolite</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofarabine</intervention_name>
    <description>Given IV.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Cl-F-Ara-A</other_name>
    <other_name>CAFdA</other_name>
    <other_name>2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine</other_name>
    <other_name>Clofarex</other_name>
    <other_name>Clolar^TM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given IV, IM or IT.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>MTX</other_name>
    <other_name>High-dose methotrexate (HD-MTX)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mercaptopurine</intervention_name>
    <description>Given PO.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>6-MP</other_name>
    <other_name>Purinethol®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Given PO or IV.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Decadron®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <description>Given IT.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Cortef®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>VP-16</other_name>
    <other_name>Vepesid®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of newly diagnosed lymphoblastic lymphoma (patients must have &lt;25% tumor&#xD;
             cells in bone marrow by morphology)&#xD;
&#xD;
          2. Age ≤ 21 years&#xD;
&#xD;
          3. Limited prior therapy, including systemic glucocorticoids for 1 week or less, 1 dose&#xD;
             of vincristine, emergency radiation therapy to the mediastinum, and 1 dose of IT&#xD;
             chemotherapy. Other circumstances must be cleared by PI or co-PI.&#xD;
&#xD;
          4. Written, informed consent and assent following guidelines of the Institutional Review&#xD;
             Board, National Cancer Institute (NCI), Food and Drug Administration (FDA), and Office&#xD;
             of Human Research Protections (OHRP).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participants with prior therapy, other than therapy specified in 3 above.&#xD;
&#xD;
          2. Participants who are pregnant or lactating.&#xD;
&#xD;
          3. Inability or unwillingness of research participant or legal guardian/representative to&#xD;
             give written informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroto Inaba, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rady Children's Hospital San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stjude.org</url>
    <description>St. Jude Children's Research Hospital</description>
  </link>
  <link>
    <url>http://www.stjude.org/protocols</url>
    <description>Clinical Trials Open at St. Jude</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 17, 2011</study_first_submitted>
  <study_first_submitted_qc>October 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2011</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoblastic lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>Mercaptopurine</mesh_term>
    <mesh_term>Clofarabine</mesh_term>
    <mesh_term>Thioguanine</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Antimetabolites</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

